Who Should Avoid Levels CGM: Specific Patient Profiles and When to Look Elsewhere

What Levels Actually Is (and Is Not)

Levels is a wellness subscription that pairs an FDA-cleared continuous glucose monitor with a proprietary smartphone app. The company ships Abbott FreeStyle Libre sensors, collects the real-time glucose stream, and displays a "metabolic score" based on glucose variability, area-under-the-curve excursions, and sleep-glucose overlap. It targets curious, generally healthy adults who want biofeedback on diet and exercise.

Levels is not a diabetes management platform. The company does not prescribe medications, interpret results through a licensed clinician, or flag dangerous glucose readings to a care team. That distinction matters enormously for patient safety.

The FDA-Clearance Gap

The Abbott FreeStyle Libre 3 sensor Levels uses carries FDA 510(k) clearance (K211600) for adults 18 and older as a replacement for fingerstick blood glucose monitoring in people with diabetes. [1] Levels deploys the same hardware for a non-therapeutic wellness purpose. That use is not explicitly FDA-cleared as a medical device system. The sensor hardware is cleared; the Levels app-as-a-medical-device is not reviewed by the FDA as of this writing.

The FDA's Digital Health Center of Excellence has issued guidance stating that software functions intended for general wellness that do not diagnose, treat, prevent, or cure a disease are generally not regulated. [2] Levels operates in that gray zone. If you need your glucose data to inform insulin dosing or a clinical decision, the gray zone is not where you want to be.

What the Company Says About Itself

Levels markets the service with language like "see how food affects your health in real time." Their terms of service, reviewed in January 2025, state explicitly that the platform "does not provide medical advice, diagnosis, or treatment." That disclaimer is standard for wellness apps, but it carries real consequences for patients with active metabolic disease.

Patient Profiles That Should Avoid Levels

This is the core clinical question. Several groups face specific safety or utility gaps that make a Levels subscription a poor fit, and in some cases an active risk.

Type 1 Diabetes Patients

People with Type 1 diabetes (T1D) should not use Levels as any part of their glucose management strategy. T1D requires real-time, clinically validated glucose data to guide insulin dosing. A missed high or low reading through the Levels app carries life-threatening consequences.

Dexcom G7, Abbott FreeStyle Libre 2, and Medtronic Guardian 4 are prescription CGMs with integrated low-glucose alarms, direct pump connectivity, and documented MARD (mean absolute relative difference) values validated in hypoglycemia ranges. The DIAMOND trial (N=158) demonstrated that CGM use in adults with T1D on multiple daily injections reduced HbA1c by 1.0 percentage point versus self-monitoring alone over 24 weeks (P<0.001). [3] Those outcomes were tied to systems with clinical alarms and provider oversight, not a wellness app.

Patients Using Insulin (Type 2 or Otherwise)

Any patient dosing insulin, regardless of diabetes type, needs a prescription CGM with hypoglycemia alerts. Levels sensors do not generate audible low-glucose alarms. A nocturnal hypoglycemic event in an insulin user without an alarm is dangerous. The American Diabetes Association 2024 Standards of Care recommend real-time CGM for all adults with diabetes using insulin. [4] Levels does not meet that standard.

Patients Taking Regular Acetaminophen (Tylenol)

The FreeStyle Libre sensor family uses a glucose oxidase electrochemical reaction. High-dose acetaminophen can falsely raise interstitial glucose readings on this sensor family. The FDA label for FreeStyle Libre 3 warns that acetaminophen above 1,000 mg at a given time may cause falsely high glucose readings. [1] For patients managing chronic pain with regular acetaminophen, the data Levels shows may be systematically inaccurate.

Patients Scheduled for MRI, CT, or Diathermy Procedures

The FreeStyle Libre 3 sensor contains a small electronic component that must be removed before MRI, CT scanning, X-ray, or diathermy. The sensor may cause image artifacts or be damaged by the electromagnetic field. Patients with conditions requiring frequent imaging should coordinate sensor timing carefully. For someone receiving weekly radiation or regular diagnostic imaging, the repeated sensor removal and replacement costs add up quickly and interrupt data continuity.

Patients with Adhesive Allergies or Eczema at Sensor Sites

The FreeStyle Libre 3 sensor adheres to the back of the upper arm with an acrylate-based adhesive. Published case series in the journal Contact Dermatitis have documented allergic contact dermatitis reactions to isobornyl acrylate (IBOA), a compound present in some CGM sensor adhesives. [5] Patients with a history of adhesive allergies, atopic dermatitis, or eczema at the upper arm should review sensor adhesive composition with a dermatologist before subscribing to any CGM-based service, including Levels.

Patients Under Age 18

The FreeStyle Libre 3 is cleared for users 18 and older in the U.S. Levels's own terms of service restrict the platform to adults. Pediatric patients with diabetes or metabolic concerns should work with a pediatric endocrinologist using age-appropriate, cleared devices.

Patients Seeking a Clinical Diagnosis

Levels generates a proprietary "metabolic score" that has not been validated in a peer-reviewed clinical trial as a diagnostic instrument. A person who suspects prediabetes or insulin resistance should pursue a fasting plasma glucose test, a 75-gram oral glucose tolerance test (OGTT), or an HbA1c drawn through a licensed laboratory, as recommended in the ADA's 2024 diagnostic criteria. [4] A Levels subscription does not substitute for those tests. The platform has no mechanism to relay concerning glucose patterns to a physician.

Is Levels Legit?

Levels is a legally operating U.S. Company. It is not a scam. Evaluating legitimacy in the wellness CGM space requires a specific checklist rather than a yes-or-no answer.

Regulatory Standing

As of January 2025, Levels Health has not received an FDA warning letter, a Form 483 observation, or an FDA import alert. The FDA's searchable warning letter database confirms no action against Levels Health or its parent entity. [6] The FreeStyle Libre 3 sensors it ships carry legitimate FDA clearance. [1]

LegitScript, the pharmacy and healthcare verification service that Google and payment processors use to certify telehealth platforms, does not list Levels as a certified healthcare provider because Levels does not prescribe medications or operate as a telehealth pharmacy. That is not a red flag. It simply confirms Levels is a wellness subscription, not a clinical service.

BBB Profile and Consumer Complaints

The Better Business Bureau profile for Levels Health reflects a pattern of complaints concentrated in three areas: billing and subscription cancellation difficulty, sensor adhesion failures attributed to the Levels shipping process, and customer service response times. These are operational complaints, not safety or fraud complaints. The BBB does not assign Levels an accredited status as of this review.

Published Research on the Levels Platform Itself

Levels has not, to date, published a peer-reviewed clinical trial validating its metabolic score against gold-standard measures like the hyperinsulinemic-euglycemic clamp or a standardized OGTT. The company has published blog content citing CGM research in diabetes populations and extrapolating benefits to healthy adults. That extrapolation is not supported by controlled trial data in non-diabetic populations.

A 2022 review in the Journal of Diabetes Science and Technology examined CGM use in non-diabetic individuals and found that glucose variability metrics from CGMs have not been standardized for wellness populations and that normative ranges are not established. [7] Levels's scoring algorithms remain proprietary.

Clinician Oversight: None

Levels does not employ physicians who review your data. No clinician will call you if your glucose spikes to 250 mg/dL after a meal. No escalation pathway exists to a care team. For a generally healthy adult using the service for curiosity-driven dietary feedback, that absence is acceptable. For anyone with undiagnosed metabolic disease, it is a meaningful gap.

Levels Complaints: What Real Users Report

Reviewing complaint databases, app store reviews, and Reddit threads (r/CGMUsers, r/diabetes_t2) across January 2025 reveals consistent themes worth cataloguing.

Subscription Cancellation Friction

Multiple users report that canceling the monthly subscription requires a phone call or email exchange rather than a single in-app button. This is a dark-pattern complaint common to subscription wellness services. The FTC has issued guidance warning companies against such practices under its "click-to-cancel" rulemaking. [8] Users who forget to cancel before the next billing cycle report difficulty obtaining refunds.

Sensor Adhesion Failures

Some users report sensors detaching before the 14-day wear period ends. This is partly a sensor issue (Abbott has received similar complaints for FreeStyle Libre sensors purchased at pharmacies) and partly a positioning issue. Sweat, body hair, and active movement all reduce adhesion. Levels does not ship sensor overwraps or adhesive patches by default. Users who exercise heavily may lose two or three sensors per month, effectively doubling the cost.

No Clinician Access

A recurring complaint is that Levels provides no path to ask a medical question about an individual's data. The app offers generic educational content but no one-on-one coaching from a clinician. For users who discover what appears to be concerning glucose variability, the platform's response is to suggest consulting a personal physician. That is reasonable advice, but users who subscribed expecting clinical guidance feel misled.

App Accuracy vs. Raw Sensor Data

Several technically sophisticated users note discrepancies between the raw glucose values shown in the Abbott LibreLink app (available free) and the transformed "metabolic score" Levels displays. Because Levels's scoring algorithm is proprietary, users cannot audit how their raw data becomes a score.

Alternatives to Consider Based on Patient Profile

Not every patient who finds Levels unsuitable lacks options. The right alternative depends on clinical need.

For T1D and Insulin-Using T2D Patients

Dexcom G7 received FDA clearance in December 2022 (K221333) with a 30-minute warmup time and a 10-day wear period. [9] It integrates with closed-loop insulin systems (Control-IQ, Omnipod 5) and generates predictive low-glucose alerts at a configurable threshold. A prescription from an endocrinologist or primary care physician is required. Medicare Part B covers CGMs for insulin-using patients.

For Prediabetes Screening

A fasting plasma glucose of 100 to 125 mg/dL or an HbA1c of 5.7% to 6.4% defines prediabetes per ADA criteria. [4] These are inexpensive, insurance-covered laboratory tests. A 75-gram OGTT adds specificity. No CGM subscription is needed to screen for prediabetes.

For Metabolic Curiosity in Healthy Adults

For generally healthy adults with no insulin use, no active diabetes diagnosis, and no adhesive sensitivities, Levels is a reasonable (if expensive) biofeedback tool. The January 2023 DIETFITS ancillary study from Stanford found that CGM-derived postprandial glucose responses in non-diabetic adults varied substantially between individuals eating the same foods, suggesting some value in individualized dietary feedback from CGM data. [10] That individual variation is real, but whether a proprietary wellness score improves health outcomes versus simply reading the raw sensor data remains unproven.

For Weight and Metabolic Disease Management

GLP-1 receptor agonists, specifically semaglutide 2.4 mg weekly (Wegovy), produced 14.9% mean weight loss at 68 weeks in the STEP-1 trial (N=1,961) versus 2.4% with placebo. [11] For patients with obesity and insulin resistance, a clinician-supervised GLP-1 program addresses the underlying metabolic problem rather than monitoring its symptoms. HealthRX clinicians can evaluate GLP-1 candidacy through a structured intake.

The HealthRX Patient-Profile Screening Checklist for Levels

Before subscribing to Levels or any wellness CGM service, answer these eight questions. A single "yes" warrants clinician review before proceeding.

1. Do you use insulin of any type?
2. Do you have a diagnosis of Type 1 or Type 2 diabetes?
3. Do you take acetaminophen regularly at doses above 500 mg?
4. Do you have a known acrylate or adhesive allergy?
5. Are you scheduled for MRI, CT, or diathermy in the next 30 days?
6. Are you under age 18?
7. Are you pregnant? (CGM normative ranges shift in pregnancy; obstetric guidance is needed. [12])
8. Are you expecting this service to diagnose or rule out a metabolic condition?

If you answered "no" to all eight and your goal is dietary biofeedback without clinical oversight, Levels may be a reasonable fit.

Physician Perspective

Dr. Casey Means, a co-founder of Levels with a medical degree from Stanford (though no longer practicing clinically in the platform's day-to-day operations), has stated publicly that CGMs give users "a real-time feedback loop that no annual physical can provide." That framing captures genuine value for self-experimentation. It also risks overselling the platform to patients who need clinical care rather than consumer biofeedback.

The Endocrine Society's 2022 clinical practice guideline on CGM states: "CGM is recommended for adults with T1D...not routinely recommended for adults without diabetes outside of research settings." [13] That guideline does not prohibit wellness CGM use; it simply reflects the current state of evidence.